The impact of obesity towards prostate diseases

Dyandra Parikesit, Chaidir Arief Mochtar, Rainy Umbas, Agus Rizal Ardy Hariandy Hamid

Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia

1. Introduction

Obesity has risen alarmingly within the past few years, with an incidence of approximately one case in every three adults in the USA, compared with one in six adults 2 decades ago.1 Global prevalence of obesity in men in Europe and Asia ranges from 4% to 30%.2–6 According to the Riset Kesehatan Dasar7 (Indonesia) in 2007, the prevalence of obesity in populations above 15 years of age was 10.3%. This number has grown approximately 20% within less than 5 years.8 This geographic pattern can be explained, at least in part, by different socioeconomic conditions, as well as by lifestyle (sedentary lifestyle and lack of physical activity) and nutritional factors (western diet).

It is well known that obesity is associated with an increased risk of heart disease and diabetes. Most of these excess deaths were attributed to coronary artery disease, diabetes, and kidney disease. There are no clear indications that the obesity prevalence is returning back to healthier levels.9 Recent studies have also looked into its relationship with prostate disease.10–12 The aim of this study is to evaluate the association between central obesity and prostate disease [prostatitis, benign prostate hyperplasia (BPH), and prostate cancer (PCa)].

2. Definition of obesity

The World Health Organization and The National Institutes of Health define overweight as a body mass index (BMI) of greater than 25 kg/m², and obesity as BMI of greater than 30 kg/m², whilst in Indonesia, according to the Riset Kesehatan Dasar7 by the Health Ministry in 2010, overweight is defined as a BMI of between 25 kg/m² and 27 kg/m² and obesity is more than 27.1 kg/m².8 Though easy to determine, BMI has its limitations, such as the inability to both differentiate between fat and muscle, and measure fat distribution in the body (since fat in different regions may contribute different functions), especially in elderly individuals.13–15

Central obesity is known to be more dangerous than general obesity because it is able to produce hormonal and systemic modifications leading to inflammation. Waist circumference (WC) in determining visceral adiposity has been used in various studies as an alternative measurement and definition of central obesity.10 WC can be measured either at the narrowest torso circumference or at the midpoint between the lower ribs and iliac crest.10 This relatively practical application has led to the wide use of WC in many studies as a tool to measure central obesity.18–20 The measurement of WC, which represents abdominal adipose tissue, has been reported to increase at a faster rate than BMI, which counts
the body’s entire weight including both adipose tissue and muscle mass. In addition, the adverse health consequences of obesity may be underestimated by trends of BMI. Central obesity can be diagnosed if WC is larger than 90 cm in men and 80 cm in women.

There is evidence linking the amount of adipose tissue to the level of both acute and chronic inflammation. However, there are certain types of adipose tissue, which vary from different adipose tissue location and composition, that are strongly correlated with inflammation. Adipose tissue is divided into two categories: visceral (abdominal/central) adipose tissue (VAT) and subcutaneous (peripheral) adipose tissue (SAT). VAT has a distinct characteristic in terms of function and inflammation compared to SAT. VAT is mainly composed of omental, mesenteric fat, and retroperitoneal fat masses by delineation along the dorsal borderline of the intestines and the ventral surface of the kidney. Adipocytes from VAT appear to have reduced capacity for lipogenesis and greater capacity for lipolysis than SAT cells, with VAT containing more pro-inflammatory and angiogenic cytokines than SAT. Fox et al demonstrated that the VAT compartment is metabolically active, secreting such vasoactive substances as inflammatory markers and adipocytokines, which may contribute to its role in the inflammation process. Alterations in plasma lipoprotein levels, particularly increased triglyceride and decreased high density lipoprotein levels, has also been associated with VAT distribution. Because obesity often associates with a sedentary lifestyle, and physical activity decreases the risk of prostate problems, this could suggest novel prevention and treatment strategies through weight loss and lifestyle changes.

3. Obesity and prostatitis

Prostatitis is a common but poorly defined condition, without clear diagnostic criteria and treatment approaches. Age, race, and geographic region have been identified by several studies to be a significant risk factor for chronic prostatitis. Prostatitis is found in approximately 10–14% of men of all ages and racial origin and nearly 50% of men at some point in their life encounter this condition.

There is currently no evidence about the relationship between obesity and prostatitis. Although it still remains unclear, there are few studies reviewing this relationship between obesity and prostatitis using the BMI parameter. Wallner et al showed that increased BMI has a protective effect on prostatitis risk after adjustment for age. The odds of having a history of prostatitis were decreased by approximately 68% in obese men (BMI > 30 kg/m²) when compared with men with a BMI of 25 kg/m². This result is likely due to the influence of physical activity on this relationship. This study revealed that the odds of developing prostatitis in men who were vigorously physically active were 67%. In the same study, a larger percentage (57.8%) of the men characterized as obese were found to engage in vigorous exercise compared with overweight (4.8%) and normal weight men (22.4%). Unfortunately, this particular study did not state the type of exercise performed by their participants. Studies regarding this subject are paramount in determining the risk of prostatitis in people with obesity. Thus many studies relating obesity and prostatitis are still needed and might be enlightening.

4. Obesity and BPH

BPH is the most common nonmalignant medical condition of the prostate occurring in middle aged and older men. BPH is a histological diagnosis associated with unregulated proliferation of connective tissue, smooth muscle, and glandular epithelium within the prostatic transition zone. Cellular proliferation leads to increased prostate volume and increased stromal smooth muscle tone. According to a recent epidemiological study, BPH affects 70% of men aged 60–69 years old and 80% of those ≥70 years old.

Many studies have shown that obese men have a higher risk for BPH, as shown in Table 1. Even though there are many standards, according to patients’ characteristics (e.g., race) in categorizing patients’ BMI and WC to diagnose obesity, all studies have resulted in the same conclusion that obesity, central or general, is a risk factor for BPH and worsened urinary symptoms. Increased WC was significantly and positively associated with prostate volume, serum prostate-specific antigen, and International Prostate Symptom Score, and therefore worsened the patients lower urinary tract symptoms.

There are many hypotheses that have been suggested for the effect of obesity on BPH. Central obesity exerts several systemic effects. Obesity will increase intra-abdominal pressure, which in turn increases bladder pressure and intravesical pressure, with the potential to exacerbate and cause worsened BPH symptoms. Another mechanism is altered endocrine status. Increased estrogen to androgen ratio due to the enzyme P450 aromatase expressed by fat tissue. Therefore, an adipose tissue mass will increase the aromatase activity and the conversion of the androgens to estrogens (testosterone to estradiol and androstenedione to estrone). Increased fat mass and aromatase activity reduces the testosterone concentrations and allows for the preferential deposition of abdominal adipose tissue/VAT as the positive caloric balance which results in a hypogonadal obesity cycle. Continued production of estradiol caused by fat mass accumulation may result in gonadotropin suppression, with a further reduction in the testosterone levels and the development of a progressive hypogonadal state thus favorable in the development of BPH. Increased sympathetic nervous activity in central obesity has been known to influence the development of BPH and the severity of urinary obstructive symptoms. However, difficulties in measuring sympathetic nervous activity and heterogeneity in characterizing obesity may cause lack of a conclusive relationship between sympathetic nervous activity and obesity.

Another proposed hypothesis is the inflammation process and oxidative stress. Central obesity promotes microvascular disease and inflammation, which in turn contributes to ischemia, oxidative stress, and an intraprostatic environment favorable to BPH. Changes in regulation of programmed cell death may lead to hyperplastic and precancerous transformation. In patients with central obesity, there is evidence of increased chronic inflammation cause by the secretion of inflammation cytokines by the visceral fat. Inflammation is a very intricate phenomenon involving humoral (cytokines) and cellular (leucocyte, monocyte, and macrophages) elements. In normal mechanisms, there is a balance between proinflammatory (growth factor release and angiogenesis) and anti-inflammatory (decrease of those processes) processes, leading to inflammation resolution. However, in chronic inflammation, mainly consisting of chronically activated T cells and mononuclear phagocytes, there is persistence of proinflammatory factors causing disturbances in the inflammation process. This will further promote the inflammation process by releasing more progrowth cytokines as well as various other growth factors. T cells influence matrix formation and potential epithelial secretions. They then promote prostate stromal and epithelial proliferation/hyperplasia by inducing fibromuscular
growth and by an autocrine or paracrine loop. The amount of prostate enlargement corresponds to the extent and severity of the inflammation.

There are several inflammation processes associated with BPH development in obese patients, such as toll-like receptor (TLR), cyclooxygenase-2 (COX-2), and macrophage inhibitory cytokine-1 (MIC-1). TLR is a transmembrane receptor responsible for the initiation of a range of host-defense mechanisms in response to microbial products and can be found in prostate tissue and acts as a proinflammatory cytokine. Pouliant-Godefroy et al. observed an increased expression of TLRs in VAT of approximately 1.35 to 1.4 fold compared with SAT. This expression in fat cells induces cytokine secretion, which triggers further inflammation. Chronic inflammation continuously produces COX-2, which modulates the production of angiogenic factors to induce angiogenesis, increases the carcinogenic potential of cells through the oxidation of procarcinogens to carcinogens, increases cell growth, and decreases apoptosis. Nitric oxide is one of the free radicals associated with prostatic inflammation. It enhances COX activity, which has been detected in all inflammatory cells in the epithelium and interstitial spaces of human prostate tissue. Di Silverio et al. and Hamid et al. showed that, in human BPH tissue, COX-2 could produce a significant increase in prostate cell apoptotic inhibitory activity causing cell proliferation in the prostate. The relationship between COX-2 and central obesity in humans is still debatable; however, a study by Ghoshal et al. found that in mice, genetic deficiency of COX-2 resulted in a significant reduction in total body weight and percent body fat.

Induction of anti-inflammatory factors such as MIC-1 is an early response due to inflammation in the prostate. MIC-1 was down regulated in BPH tissues compared with normal prostate tissue. This may be caused by gland destruction by inflammatory infiltrates, followed by replacement of the stromal component in symptomatic BPH. However, Dostalova et al. revealed that central obesity is associated with significantly higher serum MIC-1 levels, although the exact mechanism is still poorly understood. It is possible that expression of circulating MICs might be in a different concentration than prostatic MICs, especially in the transition zone (site of BPH).

5. Obesity and PCa

PCa is the second most commonly diagnosed cancer and the sixth most common cause of cancer-related mortality among men worldwide. According to GLOBOCAN 2012, it was shown that PCa is the third most common cancer in men (after lung and colorectal cancer) and has around a 9.8% incidence and 8.9% mortality amongst all cancers in Indonesia. Studies have reported the association between obesity and many cancers including PCa. A detailed explanation from many studies is shown in Table 2. Throughout many studies it is shown that obesity is a risk factor for the development of prostate cancer (odds ratio 1.097–2.47) and even the progression towards high grade disease (odds ratio 1.49–2.56).

| Study reference | Population studied (n) | Control (n) | Findings |
|-----------------|------------------------|------------|----------|
| Lee et al.      | WC ≥ 100 cm (119)      | WC < 90 cm (153) | Higher WC related to worse BPH symptoms (OR – 1.68, P = 0.002) |
| Giovannucci et al | WC ≥ 109 cm (258)     | WC < 80 cm (415) | Abdominal obesity associated with BPH (OR – 2.38, 95% CI 1.42–3.99) |
| Wang et al      | WC ≥ 50 cm (270)       | WC < 90 cm (216) | The only independent risk factor of BPH is abdominal overweight/obesity (OR 2.112, 95% CI 1.284–3.7; P < 0.003) |
| Rohrmann et al  | WC > 102 cm (2,797)    | WC < 94 cm (not clearly mentioned) | Higher WC was more likely to have LUTS (OR – 1.48, 95% CI 0.87–2.54). |
| Parsons et al   | BPH (91)               | Control (331) | Odds ratio for BPH |
|                 |                        |            | Overweight men (BMI, 25–29.9 kg/m²): 1.41 (95% CI, 0.84–2.37) |
|                  |                        |            | Obese men (BMI, 30–34 kg/m²): 1.27 (95% CI, 0.68–2.39) |
|                  |                        |            | Severely obese men (BMI > 35 kg/m²): 3.52 (95% CI, 1.45–8.6; P < 0.01) |
| Xie et al       | BPH (317)              | Control (332) | Overweight men increased risk of BPH (OR: 1.61, 95% CI 1.15–2.26) |
|                 |                        |            | Obese men (OR 2.07, 95% CI 1.04–4.14) |
|                 |                        |            | The OR increased 1.12-fold per increase in 1 unit of BMI (OR 95% CI 1.06–1.18) |
| Lee et al       | Obese (58)             | Normal weight (50) | Higher BMI (≥ 25 kg/m²) and central obesity were at significantly increased risk of BPH (OR = 4.88, P = 0.008) |
| Penson et al    | Severely obese (942)   | Normal weight (2,046) | Worsened BPH symptoms were significantly associated with a BMI of ≥ 35 kg/m² (OR 1.38, 95% CI 1.17–1.63). |

BMI, body mass index; BPH, benign prostate hyperplasia; CI, confidence interval; LUTS, lower urinary tract symptoms; OR, odds ratio; WC, waist circumference.
inversely to BMI. Total testosterone bioavailability, plus chemically bound/unavailable testosterone, also correlates inversely with BMI and insulin. This relationship can be explained by long-loop feedback inhibition of pituitary luteinizing hormone secretion by bioavailable (non-SHBG bound) testosterone, which leads to reduced testicular androgen synthesis. In obese men, total testosterone, SHBG, luteinizing hormone pulse amplitude, diurnal luteinizing hormone, and bioavailable testosterone are all reduced. Prabhat et al concluded that central obesity had a higher correlation with hormonal and metabolic alterations compared with BMI, which may contribute to various mechanisms, such as chronic inflammation. Central adiposity, which was evaluated in European patients at risk of PCa, is a state of chronic subclinical inflammation associated with adipokine signaling such as higher levels of leptin, lower levels of adiponectin, which have, though controversially, been associated with PCa. Leptin, the adipocyte-derived hormone, is elevated in central obesity and exerts a predominantly protumor effect in human PCa cell lines, by promoting angiogenesis and increased sympathetic nervous system activity. In contrast to leptin, adiponectin has largely antitumor effects by inhibiting cancer cell growth, metastasis, inhibiting dehydrotestosterone, and it inhibits inflammation by inhibiting the activity of mature phagocytic macrophages; however, serum levels of adiponectin are reduced in central obesity. All of these mechanisms result in increased proliferation, decreased apoptosis, and transition from androgen dependence to androgen independence. The mechanism of how obesity might affect PCa is shown in Fig. 1.

Prabhat et al concluded that central obesity had a higher correlation with hormonal and metabolic alterations compared with BMI, which may contribute to various mechanisms, such as chronic inflammation. Central adiposity, which was evaluated in European patients at risk of PCa, is a state of chronic subclinical inflammation associated with adipokine signaling such as higher levels of leptin, lower levels of adiponectin, which have, though controversially, been associated with PCa. Leptin, the adipocyte-derived hormone, is elevated in central obesity and exerts a predominantly protumor effect in human PCa cell lines, by promoting angiogenesis and increased sympathetic nervous system activity. In contrast to leptin, adiponectin has largely antitumor effects by inhibiting cancer cell growth, metastasis, inhibiting dehydrotestosterone, and it inhibits inflammation by inhibiting the activity of mature phagocytic macrophages; however, serum levels of adiponectin are reduced in central obesity. All of these mechanisms result in increased proliferation, decreased apoptosis, and transition from androgen dependence to androgen independence. The mechanism of how obesity might affect PCa is shown in Fig. 1.

It is thought that androgens might promote the initiation and progression of well-differentiated PCa, while protecting against poorly differentiated cancers. However, an increased risk for
poorly differentiated PCa has been associated with hyper-insulinemia and leptin.^{22,31,58,73,75} A recent study indicates that obese people have low testosterone levels, raised insulin and leptin, characteristics of adiposity, which increases the risk for poorly differentiated, androgen dependent PCa.^{17}

6. Conclusion

Central obesity is one of the modifiable risk factors in relation to prostate diseases. Adipose tissue, favoring VAT, is an important risk factor for the development of BPH and PCa. Many mechanisms have been hypothesized to explain the correlation between obesity and risk of BPH and PCa, such as increased estrogen-to-androgen ratio and increased sympathetic nervous activity, promotion of inflammation process, which in turn contributes to ischemia, oxidative stress, and an intraprostatic environment favorable to BPH and PCa. A greater understanding of the pathogenesis of prostate disease and adiposity could allow the development of new therapeutic markers, prognostic indicators, and drug targets. It may also provide scientific evidence to promote weight loss and other lifestyle modifications as beneficial adjuvant therapies for prostate diseases.

Conflicts of interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

1. Freedland SJ, Aronson J Jr, Kane CJ, Aronson WJ, Kane CJ, Presti Jr JC, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22:46–53.
2. Mohamud WN, Musa KI, Khir AS, Ismail AA, Ismail IS, Kadir KA, et al. Prevalence of overweight and obesity among adult Malaysians: an update. Asia Pac J Clin Nutr 2011;20:35–41.
3. Obesity: preventing and managing the global epidemic. Report of a World Health Organization (WHO) consultation. WHO technical report series 2000:894:1–xii, 1–253.
4. Jinarun N, Kosulwat V, Rojoongwasinkul N, Boonpraderm A, Haddock CK, Poston WS. Prevalence of overweight and obesity in Thai population: results of the National Thai Food Consumption Survey. Eat Weight Disord 2011;16:e242–9.
5. Florentino RF. The burden of obesity in Asia: Challenges in assessment, prevention and management. Asia Pac J Clin Nutr 2002;11(suppl 8):S576–80.
6. Deepa M, Farooq S, Deepa R, Manjula D, Mohan V. Prevalence and significance of generalized and central body obesity in an urban Asian Indian population in Chennai, India (CUREX: 47). Eur J Clin Nutr 2009;63:259–67.
7. Department of Health R.I. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS). Indonesia: Department of Health R.I.; 2007.
8. Department of Health R.I. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS). Indonesia: Department of Health R.I.; 2010.
9. Chiamie K, Oberfoell S, Kwan L, Labo J, Wei JT, Litwin MS. Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy? Urology 2013;81:849–55.
10. Hsing AW, Saloda LC, Chua Jr S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007;86:s43–57.
11. Kristal AR, Arnold KB, Shonen JA, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 2007;177:1395–400.
12. Wallner LP, Clemens JQ, Sarma AV. Prevalence of and risk factors for prostatitis in African American men: the Flint Men’s Health Study. Prostate 2009;69:24–32.
13. Garn SM, Leonard WR, Hawthorne VM. Three limitations of the body mass index. Am J Clin Nutr 1986;44:996–7.
14. McLaren DS. Three limitations of the body mass index. Am J Clin Nutr 1987;46:121.
15. Micozzi MS, Albanes D. Three limitations of the body mass index. Am J Clin Nutr 1987;46:376–7.
16. Pongchayakul C, Kosulwat V, Rojoongwasinkul N, Charoenkiatkul S, Thepsuthammarat K, Lopaiboon M, et al. Prediction of percentage body fat in rural Thai population using simple anthropometric measurements. Obes Res 2005;13:729–38.
47. Person DF, Munro HM, Signorello LB, Blot WJ, Fowke JH. Urologic Diseases in America Project. Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. J Urol 2011;186:2316–22.

48. Wang HH, Hsieh CJ, Lin KJ, Chu SH, Chuang CK, Chen HW, et al. Waist circumference is an independent risk factor for prostatic hyperplasia in Taiwanese males. Asian J Surg 2011;34:163–7.

49. Xue LP, Bai Y, Zhang XZ, Zheng XY, Yao KS, Xu L, et al. Obesity and benign prostatic enlargement: a large observational study in China. Urology 2007;69:680–4.

50. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Lavarny G, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009;182:4056–64.

51. Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2004;159:390–7.

52. Wang S, Mao Q, Lin Y, Wu J, Wang X, Zheng X, et al. Body mass index and risk of hypertension. Am J Hypertens 2009;22:745–51.

53. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, et al. Obesity and benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunction. J Endocrinol Invest 2014;37(2):230–4.

54. Williams G. Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-alpha and GPER signalling. Mol Cell Endocrinol 2012;351:269–80.

55. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Endocrinol Metab 2004;114:1752–61.

56. Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in prostate cancer. Cancer Epidemiol Biomarkers Prev 2013;22:898–904.

57. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, et al. Prostate growth and inflammation. J Steroid Biochem Mol Biol 2008;108:254–60.

58. Hsieh CJ, Wang PW, Chen TY. The relationship between regional abdominal fat distribution and both insulin resistance and subclinical chronic inflammation in non-diabetic adults. Diabetol Metab Syndr 2014;6:49.

59. Sandhu JS. Prostate cancer and chronic prostatitis. Curr Urol Rep 2008;9:328–32.

60. Karan D, Holzbeierlein J, Thrasher JB. Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer. Cancer Res 2009;69:2–5.

61. Dostalova I, Roubicek T, Bartlova M, Mraz M, Lacinova Z, Haluzikova D, et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol 2009;161:397–404.

62. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800–9.

63. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;36:8359–86.

64. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013;2013:291546. http://dx.doi.org/10.1155/2013/291546.

65. Song X, Pulkala E, Dyba T, Tuomaineh J, Molchanov V, Mannisto S, et al. Body mass index and cancer incidence: the FINRISK study. Eur J Epidemiol 2014;29:477–87.

66. Vuicnik J, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sc 2012;1271:37–43.

67. Tewari R, Rajender S, Natu SM, Dalela D, Goel A, Goel MM, et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763–76.

68. De Nunzio C, Freedland SJ, Miano L, Finazzi Agro E, Ibanez L, Tubaro A. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis. Eur J Surg Oncol 2011;37:1025–9.

69. Sarai S, Lefebvre O, Murat F, Dahmani L, Bore D. Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia. BJU Int 2003;91:482–4.

70. Nemesure B, Wu SY, Hennis A, Leske MC. Prostate Cancer in a Black Population Study Group. Central adiposity and prostate cancer in a black population. Cancer Epidemiol Biomarkers Prev 2012;21:851–8.

71. Park J, Cho SY, Lee SB, Son H, Jeong H. Obesity is associated with higher risk of prostate cancer detection in a Korean biopsy population. BJU Int 2014;114:891–5.

72. Rundle A, Jankowski M, Kryvenko ON, Tang D, Rybicki BA. Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate. Cancer Epidemiol Biomarkers Prev 2013;22:898–904.

73. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010;21:610–8.

74. Kaaks R, Stattin P. Obesity, endogenous hormone metabolism, and prostate cancer risk: a conundrum of highs and lows. Cancer Prev Res 2010;3:259–62.

75. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman Uh, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metabol 2001;86:1341–5.

76. Izadi Y, Farahabadi A, Azadkhah I. Serum adiponectin level and different kinds of cancer: a review of recent evidence. ISRN Oncol 2012;2012:982769. http://dx.doi.org/10.5402/2012/982769.

77. Lu K, Song X, Han SL, Wang CH, Zhong N, Qi LF. Potential study perspectives on mechanisms and correlations between adiposity and malignancy. Asian Pac J Cancer Prev 2014;15:1057–60.